The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | D | Dermatologicals | |
| 2 | D11 | Other dermatological preparations | |
| 3 | D11A | Other dermatological preparations | |
| 4 | D11AH | Agents for dermatitis, excluding corticosteroids | |
| 5 | D11AH07 |
| Active Ingredient | Description | |
|---|---|---|
| Tralokinumab |
Tralokinumab is a fully human IgG4 monoclonal antibody that specifically binds to the type 2 cytokine interleukin-13 (IL-13) and inhibits its interaction with the IL-13 receptors. Tralokinumab neutralises the biological activity of IL-13 by blocking its interaction with the IL-13RĪ±1/IL-4RĪ± receptor complex. IL-13 is a major driver of human type 2 inflammatory disease, such as atopic dermatitis and inhibiting the IL-13 pathway with tralokinumab in patients decreases many of the mediators of type 2 inflammation. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| ADTRALZA Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
